[go: up one dir, main page]

WO2008127456A3 - Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use - Google Patents

Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use Download PDF

Info

Publication number
WO2008127456A3
WO2008127456A3 PCT/US2007/086642 US2007086642W WO2008127456A3 WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3 US 2007086642 W US2007086642 W US 2007086642W WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3
Authority
WO
WIPO (PCT)
Prior art keywords
anesthetics
methods
attenuating
toxins
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/086642
Other languages
French (fr)
Other versions
WO2008127456A2 (en
Inventor
David M Anderson
Vincent M Conklin
Benjamin C Cameransi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyotropic Therapeutics Inc
Original Assignee
Lyotropic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Therapeutics Inc filed Critical Lyotropic Therapeutics Inc
Priority to EP07873662A priority Critical patent/EP2107904A4/en
Priority to AU2007351338A priority patent/AU2007351338B2/en
Priority to JP2009540476A priority patent/JP2010512341A/en
Priority to CA2672024A priority patent/CA2672024C/en
Publication of WO2008127456A2 publication Critical patent/WO2008127456A2/en
Publication of WO2008127456A3 publication Critical patent/WO2008127456A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.
PCT/US2007/086642 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use Ceased WO2008127456A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07873662A EP2107904A4 (en) 2006-12-07 2007-12-06 COMPOSITIONS FOR THE INVERSION AND DETOXIFICATION OF ANESTHETICS AND OTHER COMPOUNDS AND METHODS OF USE THEREOF
AU2007351338A AU2007351338B2 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
JP2009540476A JP2010512341A (en) 2006-12-07 2007-12-06 Compositions for reversal and detoxification of anesthetics and other compounds and methods of use thereof
CA2672024A CA2672024C (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86895006P 2006-12-07 2006-12-07
US60/868,950 2006-12-07

Publications (2)

Publication Number Publication Date
WO2008127456A2 WO2008127456A2 (en) 2008-10-23
WO2008127456A3 true WO2008127456A3 (en) 2008-12-11

Family

ID=39864561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086642 Ceased WO2008127456A2 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Country Status (5)

Country Link
EP (1) EP2107904A4 (en)
JP (1) JP2010512341A (en)
AU (1) AU2007351338B2 (en)
CA (1) CA2672024C (en)
WO (1) WO2008127456A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013257546B2 (en) * 2012-05-10 2017-12-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
JP6255975B2 (en) * 2012-12-27 2018-01-10 Jnc株式会社 Liquid crystal composition, antioxidant and liquid crystal display element
EP4110293A4 (en) * 2020-02-25 2024-07-10 The University of North Carolina at Chapel Hill EUTECTIC ANESTHETICS COMPOSITIONS AND THEIR APPLICATIONS
CN119500071A (en) * 2024-11-25 2025-02-25 广东龙康方承医疗器械有限公司 Toxin adsorbing protein complex, toxin removal method and toxin adsorber made thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922317A (en) * 1996-01-04 1999-07-13 The United States Of America As Represented By The Secretary Of The Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
WO2001022960A1 (en) * 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
US20030133877A1 (en) * 1997-07-21 2003-07-17 Levin Bruce H. Apparatus for directed intranasal administration of a composition
US20040143021A1 (en) * 2003-01-21 2004-07-22 Larijani Ghassem E. Compositions and methods for improving recovery after general anesthesia
WO2005034872A2 (en) * 2003-10-08 2005-04-21 Lyotropic Therapeutics, Inc. Drug-delivery vehicles based on reversed liquid crystalline phase materials
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246039T1 (en) * 1997-09-09 2003-08-15 Select Release L C COATED PARTICLES, METHOD FOR THEIR PRODUCTION AND USE
EP2142927A4 (en) * 2002-06-13 2010-01-13 Lyotropic Therapeutics Inc A nanoporous particle with a retained target
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922317A (en) * 1996-01-04 1999-07-13 The United States Of America As Represented By The Secretary Of The Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
US20030133877A1 (en) * 1997-07-21 2003-07-17 Levin Bruce H. Apparatus for directed intranasal administration of a composition
WO2001022960A1 (en) * 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
US20040143021A1 (en) * 2003-01-21 2004-07-22 Larijani Ghassem E. Compositions and methods for improving recovery after general anesthesia
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005034872A2 (en) * 2003-10-08 2005-04-21 Lyotropic Therapeutics, Inc. Drug-delivery vehicles based on reversed liquid crystalline phase materials
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction

Also Published As

Publication number Publication date
CA2672024C (en) 2014-07-08
EP2107904A2 (en) 2009-10-14
AU2007351338A1 (en) 2008-10-23
CA2672024A1 (en) 2008-10-23
WO2008127456A2 (en) 2008-10-23
EP2107904A4 (en) 2010-06-02
AU2007351338B2 (en) 2013-04-04
JP2010512341A (en) 2010-04-22

Similar Documents

Publication Publication Date Title
HK1222297A1 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
BRPI0906181A2 (en) "method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment "
EA201300556A1 (en) AMINOSPIR-SUBSTITUTED DERIVATIVES 2,3-DIHYDROIMIDAZO [1,2-С] HINAZOLINE, SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISTURBANCES AND DISEASES ASSOCIATED WITH ANGIOGENESIS
HK1247843A1 (en) Formulations for oral administration of active agents with controlled absorption profile
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
EA200701195A1 (en) CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2007100675A3 (en) Collagenase for treating cellulite
WO2009043987A9 (en) Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases
NO20092529L (en) Substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for the treatment of hyperproliferative disorders and diseases associated with angiogenesis
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
CL2009002183A1 (en) Use of a topical composition comprising 2.5% of imiquimod and a pharmaceutically acceptable vehicle to prepare a medicament useful for treating actinic keratosis; topical composition.
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
WO2008127456A3 (en) Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
BR112015030578A2 (en) pharmaceutical combinations
WO2007100435A3 (en) Use of dha and ara in the preparation of a composition for the prevention or treatment of anemia
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2007046083A3 (en) Compositions for treatment of eye diseases
IL197783A (en) Polycyclic compounds, pharmaceutical compositions comprising them and polycyclic compounds for use in the treatment of respiratory syncytial virus infections
JP2011500589A5 (en)
JP2012509124A5 (en)
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873662

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007351338

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009540476

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2672024

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007351338

Country of ref document: AU

Date of ref document: 20071206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007873662

Country of ref document: EP